TECNIS Multifocal Toric II IOL +3.25D

TECNIS™ Multifocal Toric II IOL +3.25D

TECNIS Multifocal 1-Piece IOLs give your patients outcomes with increased spectacle independence1 distinctly suited to their visual lifestyles.

TECNIS Multifocal IOL +3.25 D delivers outstanding visual quality tailored for longer reading distances.

TECNIS™ Multifocal Toric II IOL +3.25D

TECNIS Multifocal 1-Piece IOLs give your patients outcomes with increased spectacle independence1 distinctly suited to their visual lifestyles.

TECNIS Multifocal IOL +3.25 D delivers outstanding visual quality tailored for longer reading distances.

Key Features

Outstanding visual quality

Optimized for longer reading distances.

Enhanced functionality

Give your patients a lens designed for real-world performance.

Long-term sustainability

TECNIS IOL material is not associated with glistenings.2-6

Astigmatism correcting

Toric II technology to address astigmatism.

Learn More

Get the latest news and product info from Johnson & Johnson Vision.

Required fields are marked with an asterisk *

*

*

*

*

Your Role

*

*

Area of Interest

*

Cataract Surgery

OS Disease

LASIK Surgery

Send me updates and helpful resources via email

*

With your consent, we will use your information to send you information about our products and services tailored to your interests through email. You may withdraw your consent at any time.

Please read our Privacy Policy.

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

REFERENCES

1. TECNIS Multifocal 1-Piece IOL DFU, Models ZKB00 and ZLB00. Santa Ana, Calif. Johnson & Johnson Surgical Vision, Inc.
2. Christiansen G, et al. Glistenings in the AcrySof® intraocular lens: Pilot study. J Cataract Refract Surg. 2001;27(5):728-733.
3. Colin J, et al. Incidence of glistenings with the latest generation of yellow-tinted hydrophobic acrylic intraocular lenses. J Cataract Refract Surg. 2012;38(7):1140-1146.
4. Gunenc U, et al. Effects on visual function of glistenings and folding marks in AcrySof® intraocular lenses. J Cataract Refract Surg. 2001;27(10):1611-1614.
5. Van der Mooren M, Franssen L, Piers P. Effects of glistenings in intraocular lenses. Biomed Opt Express. 2013;4(8):1294-1304.
6. Calculated based on Holladay I formula: Holladay JT, Prager TC, Chandler TY, Musgrove KH, Lewis JW, Ruis RS. A three-part system for refining intraocular lens power calculations. J Cataract Refract Surg. 1988;14(1)17-24

INDICATIONS AND IMPORTANT SAFETY INFORMATION for the TECNIS Multifocal Toric II IOLs
Rx Only

INDICATIONS
The TECNIS Multifocal Toric II lens models ZKU150, ZKU225, ZKU300, ZKU375 and ZLU150, ZLU225, ZLU300, ZLU375 are indicated for primary implantation for the visual correction of aphakia and for reduction of residual refractive astigmatism in adult patients with or without presbyopia, with greater than or equal to 1 diopter of preexisting corneal astigmatism, in whom a cataractous lens has been removed in order to provide near, intermediate and distance vision. The IOLs are intended for capsular bag placement only.

WARNINGS
Physicians considering lens implantation should weight the potential risk/benefit ratio for any conditions described in the Directions for Use that could increase complications or impact patient outcomes. Multifocal IOL implants may be inadvisable in patients where central visual field reduction may not be tolerated, such as macular degeneration, retinal pigment epithelium changes, and glaucoma. The lens should not be placed in the ciliary sulcus. Inform patients about the possibility that a decrease in contrast sensitivity and an increase in visual disturbances may affect their ability to drive a car under certain environmental conditions, such as driving at night or in poor visibility conditions. The clinical study of the TECNIS Toric 1-Piece IOL did not show evidence of effectiveness for the treatment of preoperative corneal astigmatism of less than one diopter. Rotation of the TECNIS Multifocal Toric II IOL away from its intended axis can reduce its astigmatic correction. Misalignment greater than 30° may increase postoperative refractive cylinder.

PRECAUTIONS
Prior to surgery, inform prospective patients of the possible risks and benefits associated with the use of this device and provide a copy of the patient information brochure to patient. Secondary glaucoma has been reported occasionally in patients with controlled glaucoma who received TECNIS Multifocal IOL implants. The long term effects of intraocular lens implantation have not been determined.
Accurate keratometry and biometry in addition to the use of the TECNIS Toric Calculator (www.TecnisToricCalc.com) are recommended to achieve optimal visual outcomes with TECNIS Multifocal Toric II IOLs. The safety and effectiveness of the toric intraocular lens have not been substantiated in patients with certain preexisting ocular conditions and intraoperative complications. All preoperative surgical parameters are important when choosing a toric lens for implantation. Variability in any of the preoperative measurements can influence patient outcomes. All corneal incisions were placed temporally in the TECNIS Toric 1-Piece IOL clinical study. Do not reuse, resterilize, or autoclave.

ADVERSE EVENTS
Only the rate (3.3%) of surgical re-interventions, most of which were non-lens-related, in the ZLB00 (+3.25 D) lens group, was statistically higher than the FDA grid rate (for both first and second eyes). The most frequently reported cumulative adverse event that occurred during the TECNIS Toric 1-Piece IOL clinical trial was surgical re-intervention which occurred at a rate of 3.4% (lens repositioning procedures and retinal repair procedures).

ATTENTION
Reference the Directions for Use for a complete listing of Indications and Important Safety Information.

PP2023CT5067

Johnson & Johnson MedTech

We support the AdvaMed Code of Ethics on interacting with Healthcare Professionals.

Advamed Logo

© Johnson & Johnson Vision Care, Inc. and Johnson & Johnson Surgical Vision, Inc. 2024 All rights reserved. This site is published by Johnson & Johnson Vision Care, Inc. and Johnson & Johnson Surgical Vision, Inc., which are solely responsible for its content.

Third party trademarks used herein are trademarks of their respective owners.

Vision Made Possible